人民财讯8月14日电，国药一致（000028）8月14日晚间披露2025年半年度业绩快报，2025年上半年，公 司实现营业收入367.97亿元，同比下降2.62%；归属于上市公司股东的净利润为6.66亿元，同比下降 10.43%。 ...

Core Insights - The company reported a decline in both revenue and net profit for the first half of 2025, with revenue at 36.797 billion yuan, down 2.62% year-on-year, and net profit at 666 million yuan, down 10.43% year-on-year [1][2]. Distribution Segment - The distribution segment generated revenue of 26.783 billion yuan, a decrease of 1.09% year-on-year, and net profit of 482 million yuan, down 7.82% year-on-year, primarily due to changes in industry policies and intensified market competition [2]. - An increase in long-term accounts receivable due to delayed payments from downstream customers led to a rise in bad debt provisions, contributing to the profit decline [2]. Retail Segment - The retail segment, represented by "Guoyao Holdings Guoda Pharmacy Co., Ltd." (Guoda Pharmacy), achieved revenue of 10.479 billion yuan, a decrease of 6.46% year-on-year, but net profit increased by 215.81% to 17 million yuan [2]. - The decline in sales revenue for Guoda Pharmacy was influenced by market conditions, competitive landscape, and strategic store closures, while profitability improved through optimization of procurement systems and business structures, as well as a focus on enhancing store operational quality [2].

Core Viewpoint - The company reported a decline in key financial metrics for the first half of 2025, indicating challenges in both distribution and retail segments due to market competition and policy changes [2][3]. Financial Performance - Total operating revenue for the first half of 2025 was 3,679.66 million yuan, a decrease of 2.62% compared to the previous year [2]. - Operating profit decreased by 2.36% to 926.50 million yuan [2]. - Total profit fell by 4.16% to 918.11 million yuan [2]. - Net profit attributable to shareholders was 666.91 million yuan, down 10.43% year-on-year [2]. - Basic earnings per share decreased by 10.45% to 1.20 yuan [2]. - The weighted average return on equity declined by 0.49 percentage points to 3.70% [2]. - Total assets increased by 6.04% to 5,042.61 million yuan [2]. - Shareholders' equity attributable to the company rose by 2.64% to 1,813.62 million yuan [2]. Segment Performance - The distribution segment generated operating revenue of 26,783 million yuan, a decline of 1.09%, with net profit down 7.82% to 482 million yuan, impacted by industry policy changes and increased market competition [2]. - The retail segment, represented by "Guoyao Holdings Guoda Pharmacy Co., Ltd.", achieved operating revenue of 10,479 million yuan, a decrease of 6.46%, but net profit increased by 215.81% to 17 million yuan due to strategic store closures and cost reductions [2]. Strategic Direction - The company aims to adapt to industry policy changes and market trends by focusing on "increasing revenue, reducing costs, and improving efficiency" while accelerating digital transformation and enhancing management practices [3].

国药一致(000028.SZ)公告称，2025年上半年实现营业收入367.97亿元，同比下降2.62%；归属于上市公 司股东的净利润6.66亿元，同比下降10.43%。 ...

[Sinopharm Accord Medicine Co., Ltd. 2025 H1 Preliminary Earnings Report](index=1&type=section&id=%E5%9B%BD%E8%8D%AF%E9%9B%86%E5%9B%A2%E4%B8%80%E8%87%B4%E8%8D%AF%E4%B8%9A%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B82025%E5%B9%B4%E5%8D%8A%E5%B9%B4%E5%BA%A6%E4%B8%9A%E7%BB%A9%E5%BF%AB%E6%8A%A5) [Key Financial Data and Indicators](index=1&type=section&id=%E4%B8%80%E3%80%81%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) The company's core financial indicators showed a downward trend in H1 2025, while total assets expanded Key Financial Data for H1 2025 | Key Financial Indicator | Current Period | Prior Year Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | **Total Operating Revenue** | CNY 36.80 billion | CNY 37.79 billion | -2.62% | | **Operating Profit** | CNY 926.50 million | CNY 948.86 million | -2.36% | | **Total Profit** | CNY 918.11 million | CNY 957.97 million | -4.16% | | **Net Profit Attributable to Shareholders** | CNY 665.91 million | CNY 743.49 million | -10.43% | | **Net Profit after Non-recurring Items** | CNY 642.86 million | CNY 711.38 million | -9.63% | | **Basic Earnings Per Share (CNY)** | 1.20 | 1.34 | -10.45% | | **Weighted Average ROE** | 3.70% | 4.19% | Down 0.49 p.p. | | **Total Assets** | CNY 50.43 billion | CNY 47.56 billion | 6.04% | | **Equity Attributable to Shareholders** | CNY 18.14 billion | CNY 17.67 billion | 2.64% | [Explanation of Operating Performance and Financial Condition](index=2&type=section&id=%E4%BA%8C%E3%80%81%E7%BB%8F%E8%90%A5%E4%B8%9A%E7%BB%A9%E5%92%8C%E8%B4%A2%E5%8A%A1%E7%8A%B6%E5%86%B5%E6%83%85%E5%86%B5%E8%AF%B4%E6%98%8E) Overall performance was under pressure due to setbacks in the distribution business, partially offset by significant profit growth in the retail segment [Segment Performance Analysis](index=2&type=section&id=%E5%88%86%E9%83%A8%E4%B8%9A%E7%BB%A9%E5%88%86%E6%9E%90) The performance of the two core business segments diverged, with the distribution segment declining while the retail segment achieved significant profit growth Segment Performance for H1 2025 | Segment | Operating Revenue (CNY billion) | YoY Change | Net Profit (CNY million) | YoY Change | | :--- | :--- | :--- | :--- | :--- | | **Distribution** | 26.78 | -1.09% | 482 | -7.82% | | **Retail** | 10.48 | -6.46% | 17 | +215.81% | - The distribution segment's performance declined due to **industry policy changes**, **intensified market competition**, and **increased provisions for bad debts** from delayed customer payments[5](index=5&type=chunk) - The retail segment's profit surged due to an **optimized procurement system**, **strategic store closures**, and **improved single-store operational quality**, which reduced labor and rental costs[5](index=5&type=chunk) [Other Influencing Factors and Future Outlook](index=2&type=section&id=%E5%85%B6%E4%BB%96%E5%BD%B1%E5%93%8D%E5%9B%A0%E7%B4%A0%E5%8F%8A%E6%9C%AA%E6%9D%A5%E5%B1%95%E6%9C%9B) A decline in investment income from key associate companies negatively impacted overall profit, prompting a future focus on efficiency and digital transformation - Performance decline in key associate companies, affected by industry policies and market dynamics, led to a **reduction in the company's recognized investment income**[6](index=6&type=chunk) - Future strategy will focus on **revenue generation, cost reduction, and efficiency improvement** by accelerating digital transformation and deepening refined management[6](index=6&type=chunk) [Documents for Inspection](index=3&type=section&id=%E4%B8%89%E3%80%81%E5%A4%87%E6%9F%A5%E6%96%87%E4%BB%B6%E7%9B%AE%E5%BD%95) Reference documents include the comparative balance sheet and income statement, signed and sealed by the company's key management personnel - The documents available for inspection are the comparative balance sheet and income statement, signed and sealed by management[8](index=8&type=chunk)

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.01% on August 13, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with the following notable movements: - Seli Medical (603716) rose by 6.55% to a closing price of 31.09, with a trading volume of 556,200 shares and a transaction value of 1.671 billion [1] - Guofa Co. (600538) increased by 1.75% to 6.38, with a trading volume of 129,600 shares [1] - Huaren Health (301408) fell by 1.76% to 15.11, with a trading volume of 179,600 shares and a transaction value of 271 million [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 33.73 million from institutional investors, while retail investors experienced a net outflow of 42.05 million [2] - Notable capital flows for specific stocks included: - Seli Medical had a net inflow of 10.9 million from institutional investors, while retail investors saw a net outflow of 2.46 million [3] - Yiyang Pharmaceutical (301015) had a net inflow of 6.29 million from institutional investors, but retail investors faced a net outflow of 31.02 million [3]

Core Viewpoint - The company, China National Pharmaceutical Group Corporation (国药一致), has no plans to transition into the molecular diagnostics sector, maintaining its focus on pharmaceutical distribution and retail [2] Company Summary - The main business of the company is pharmaceutical distribution and retail [2] - The company responded to an investor inquiry regarding potential transformation into the molecular diagnostics sector, confirming that there are currently no plans for such a transition [2]

Core Viewpoint - The company has approved a profit distribution plan for the fiscal year 2024, which includes a cash dividend of RMB 3.66 per 10 shares, totaling RMB 203.7 million to be distributed to shareholders [1][5][3]. Group 1: Profit Distribution Plan - The profit distribution plan was approved at the annual shareholders' meeting held on June 10, 2025, based on a total share capital of 556,565,077 shares [1][2]. - The total cash dividend to be distributed amounts to RMB 203,702,818.18, with no stock dividends or capital reserve transfers [1][5]. - The cash dividend will be distributed to all shareholders, with specific tax implications based on the type of shares held [5][6]. Group 2: Dividend Payment Details - The cash dividend of RMB 3.66 per 10 shares is inclusive of tax, with different tax treatments for various types of shareholders [5][6]. - The A-share equity registration date is set for June 24, 2025, and the ex-dividend date is June 25, 2025 [7]. - B-share shareholders will have their last trading day on June 24, 2025, with the same ex-dividend date of June 25, 2025 [7][8]. Group 3: Distribution Method - The cash dividends for A-share shareholders will be directly credited to their accounts through their custodial securities companies on June 25, 2025 [9]. - B-share dividends will be credited on June 27, 2025, with specific instructions for shareholders who may need to handle tax-related issues [9][10]. - The company will bear all legal responsibilities for any discrepancies in the dividend distribution process [9].

国药集团一致药业股份有限公司 2024年年度权益分派实施公告 本公司及董事保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 一、股东大会审议通过利润分配方案情况 1、国药集团一致药业股份有限公司（以下简称"公司"或"本公 司"）2024 年年度利润分配方案已经公司于 2025 年 6 月 10 日召开的 2024 年年度股东大会审议通过，以公司当前总股本 556,565,077 股为基 数，向全体股东每 10 股派发现金股利人民币 3.660000 元（含税），共 计派发现金红利人民币 203,702,818.18 元，不送股，不进行资本公积金 转增股本。 证券代码：000028、200028 证券简称：国药一致、一致B 公告编号：2025-33 若在利润分配方案实施前，公司总股本发生变动的，公司将按照分 配总额不变的原则对分配比例进行调整。 2、自 2024 年年度权益分派方案披露至实施期间，公司股本总额未 发生变化。 3、本次实施的分派方案与股东大会审议通过的分派方案一致。 4、本次实施的分派方案距离股东大会审议通过的时间未超过两个 月。 二、权益分派方案 公司 2024 年年度 ...

General Principles - The rules are established to clarify the responsibilities and decision-making procedures of the board of directors of China National Pharmaceutical Group Corporation [1] - The rules aim to enhance the efficiency of board meetings and ensure scientific decision-making in accordance with relevant laws and regulations [1] Rights and Obligations of Directors - Directors have the right to attend board meetings and exercise voting rights [2] - Directors must act in the best interest of the company and adhere to legal and regulatory obligations [2][3] - Directors are required to treat all shareholders fairly and must not exploit their position for personal gain [2] Responsibilities of Directors - Directors must avoid conflicts of interest and are prohibited from misappropriating company assets or funds [2] - Directors are obligated to maintain confidentiality regarding company secrets even after their term ends [5] - Directors must sign written confirmations for periodic reports to ensure the accuracy and completeness of disclosed information [2] Board Authority - The board is responsible for convening shareholder meetings and executing shareholder resolutions [15] - The board has the authority to decide on major operational plans, investment proposals, and financial distributions [15] - The board must approve external guarantees exceeding certain thresholds based on the company's audited net assets [6] Meeting Procedures - Board meetings can be regular or temporary, with specific notification requirements for each type [12][13] - A quorum of more than half of the directors is required for meetings to be valid [15] - Decisions are made through various voting methods, including show of hands or written ballots [15][16] Committees and Roles - The board may establish specialized committees for strategic, risk control, and audit purposes [12] - The chairman of the board acts as the legal representative and is elected by the board members [17] - The board secretary is responsible for preparing meeting materials and maintaining records [12][17] Disclosure and Compliance - Major resolutions must be reported to the Shenzhen Stock Exchange within two working days [17] - The board must ensure that all meeting records are kept for at least ten years [17] - Any significant internal control deficiencies must be disclosed promptly [10]